RhAPPcast
This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases.
Episodes
In this episode of RhAPPcast, Amanda Mixon, PA-C, President of RhAPP, sits down with Kyle George, PA-C, to explore the real-world impact of Guselkumab in Psoriatic Arthritis (PsA) management. As a leading IL-23 inhibitor, Guselkumab offers durable efficacy, strong persistence, and a favorable safety profile, making it a key option for biologic-naïve patients and those with TNF inhibitor failure.
Clinical trials like VOYAGE, NAVIGATE...
Learn about the safety profile and monitoring requirements of voclosporin for lupus nephritis with Jessica Farrell, PharmD, an experienced rheumatology pharmacist and faculty member at the Albany College of Pharmacy and Health Sciences. In this video, Jessica Farrell explains what makes voclosporin—a second-generation calcineurin inhibitor—unique, including its increased potency, improved pharmacokinetic profile, and reduced need f...
Join Danielle Gatti Palumbo, PharmD, a clinical pharmacist, RhAPP faculty member, and RhAPP Board member, as she breaks down a network meta-analysis evaluating the efficacy of biologics with and without methotrexate (MTX) in the treatment of psoriatic arthritis (PsA). This insightful journal club discussion highlights key findings on whether MTX is necessary as background therapy when initiating biologics.
Methotrexate, while common...
Join Jessica Farrell, PharmD, professor at the Albany College of Pharmacy and Health Sciences and clinical pharmacist at Albany Medical Center, as she breaks down the pivotal AURORA 1 and AURORA 2 clinical trials evaluating voclosporin for lupus nephritis. Learn how this second-generation calcineurin inhibitor demonstrated superior renal outcomes, including higher complete and partial renal response rates and faster time to improve...
Join Danielle Gatti Palumbo, Clinical Pharmacist at Northwell Health’s Division of Rheumatology in Long Island, New York, as she provides a comprehensive review of Voclosporin (Lupkynis), an FDA-approved calcineurin inhibitor (CNI) for the treatment of lupus nephritis. This discussion is essential for healthcare professionals, pharmacists, and patients seeking a deeper understanding of how Voclosporin enhances lupus nephritis manag...
In this expert breakdown, Cassie Dolecki, PharmD, a clinical pharmacy specialist in rheumatology at Allegheny Health Network in Pittsburgh, Pennsylvania, discusses the effectiveness of Guselkumab across the GRAPPA domains, drawing insights from the DISCOVER-2 trial and additional post-hoc analyses.
As a phase 3 clinical trial, DISCOVER-2 evaluated Guselkumab in biologic-naïve patients with active PsA over two years, comparing 100 mg...
In this expert discussion, Katie Springer, PA-C, a rheumatology specialist with Northwestern Medicine in Chicago, Illinois, explores the effectiveness of IL-17 inhibitors in managing the nail-DIP complex in psoriatic arthritis. Nail involvement in PsA is more than just a cosmetic concern—it is strongly linked to DIP joint disease and systemic enthesitis. The nail itself is now understood to be an enthesial site, which means nail di...
In this video, Lisa Asfahani, PA-C, shares clinical insights on the evolving role of calcineurin inhibitors (CNIs) in the treatment of lupus nephritis (LN), as outlined in the new 2024 ACR Guidelines. With over 11 years of experience in rheumatology at a private practice in Temecula, California, Lisa walks through the mechanism of action of CNIs—including how they inhibit IL-2 production by binding to cytoplasmic receptors like imm...
In this essential episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by lupus expert and RhAPP faculty member Monica Richey, NP, to discuss the latest ACR guidelines for lupus nephritis and what they mean for advanced practice providers (APPs). Together, they explore how these updated recommendations mark a significant shift in treatment—highlighting triple imm...
Join Audrey Gibson, PA-C, from the Arthritis Center of North Georgia, as she explores the latest clinical comparisons between IL-17 and IL-23 inhibitors in managing moderate-to-severe plaque psoriasis (PsO) and psoriatic arthritis (PsA).
The ECLIPSE trial, published in The Lancet, compared Guselkumab (IL-23 inhibitor) vs. Secukinumab (IL-17 inhibitor) over 48 weeks. Guselkumab showed superior long-term efficacy, with 84% of patients...
Join Jessica Farrell, PharmD, a clinical pharmacist at Albany Med’s Division of Dermatology and professor at Albany College of Pharmacy and Health Sciences, as she explores a key head-to-head clinical trial comparing Ixekizumab (IL-17 inhibitor) vs. Guselkumab (IL-23 inhibitor) for moderate-to-severe plaque psoriasis. This British Journal of Dermatology study, published in December 2019, provides essential insights into efficacy, s...
Join Danielle Gatti Palumbo, Clinical Pharmacist at Northwell Health's Division of Rheumatology in Long Island, New York, as she provides an in-depth breakdown of the mechanism of action of Voclosporin (Lupkynis), a next-generation calcineurin inhibitor used in the treatment of lupus nephritis and other autoimmune diseases.
Voclosporin plays a critical role in immune modulation by inhibiting calcineurin, a key enzyme responsible for...
The 2024 ACR guidelines introduce important updates for the screening, treatment, and monitoring of lupus nephritis, with a focus on preserving renal function, reducing chronic kidney disease morbidity, and minimizing medication-related toxicities. In this video, Lisa Asfahani, PA-C, a rheumatology expert with over 11 years of experience, breaks down these new recommendations.
She discusses the importance of screening all lupus pat...
Join Amber Hudgins, PharmD, a pharmacist specializing in rheumatology and specialty pharmacy at Novant Health in Winston-Salem, North Carolina, as she provides a concise yet insightful review of the long-term safety of Guselkumab in patients with psoriatic disease, including psoriasis and psoriatic arthritis.
This discussion highlights a comprehensive integrated analysis of 11 Phase 2 and Phase 3 clinical studies, which pooled over ...
Join Danielle Gatti Palumbo, PharmD, a clinical pharmacist and RhAPP Board member, alongside Monica Richey, NP, a renowned rheumatology specialist and educator, as they discuss a challenging and unexpected clinical case live from the RhAPP National Conference in Nashville, Tennessee.
This special RhAPPcast episode explores a real-world scenario of a patient who unexpectedly became pregnant while on leflunomide, highlighting the comp...
Stacey Johnson, NP, a rheumatology specialist at Montana Arthritis Center, discusses key updates in the 2024 American College of Rheumatology (ACR) guidelines for lupus nephritis, with a strong emphasis on minimizing glucocorticoid exposure to prevent long-term complications.
The updated guidelines focus on achieving a daily glucocorticoid dose of 5 mg or less within six months of initiating therapy. This approach aims to reduce ste...
Join Katie Springer, PA-C, a rheumatology specialist at Northwestern Medicine in Lake Forest, Illinois, as she dives into critical tools for measuring disease activity in psoriatic arthritis (PsA) and how they shape treatment strategies for improved patient outcomes.
Accurate assessment of PsA requires disease-specific tools beyond traditional rheumatoid arthritis (RA) measures. The Disease Activity in Psoriatic Arthritis (DAPSA) sc...
Claudia Rivera Salas, DNP, a nurse practitioner at Pine Hollow Partners in East Lansing, Michigan, shares firsthand insights into the rapid efficacy of Ixekizumab in treating psoriasis and psoriatic arthritis. One of the most common questions patients ask is how quickly they can expect relief, and the answer is simple—fast.
From the first injection, many patients begin to see significant improvement in their symptoms, including redu...
Monica Richey, NP, a seasoned rheumatology specialist with two decades of experience, provides an in-depth review of the 2024 lupus nephritis screening and diagnosis guidelines. As systemic lupus erythematosus (SLE) remains a leading cause of kidney-related complications, early detection and accurate diagnostic methods are essential for improving patient outcomes.
This expert-led discussion explores the latest best practices for lup...
In this episode of RhAPPcast, Amanda Mixon, PA-C, President of RhAPP and a practicing physician assistant in Northern Colorado, is joined by Jennifer Mylod, NP, a seasoned rheumatology provider at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, to discuss the latest American College of Rheumatology (ACR) guideline updates for lupus nephritis.
With the first ACR guideline update since 2012, these new recommendation...
Popular Podcasts
The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy And Charlamagne Tha God!
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Welcome to "Decisions, Decisions," the podcast where boundaries are pushed, and conversations get candid! Join your favorite hosts, Mandii B and WeezyWTF, as they dive deep into the world of non-traditional relationships and explore the often-taboo topics surrounding dating, sex, and love. Every Monday, Mandii and Weezy invite you to unlearn the outdated narratives dictated by traditional patriarchal norms. With a blend of humor, vulnerability, and authenticity, they share their personal journeys navigating their 30s, tackling the complexities of modern relationships, and engaging in thought-provoking discussions that challenge societal expectations. From groundbreaking interviews with diverse guests to relatable stories that resonate with your experiences, "Decisions, Decisions" is your go-to source for open dialogue about what it truly means to love and connect in today's world. Get ready to reshape your understanding of relationships and embrace the freedom of authentic connections—tune in and join the conversation!
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
ALL THE SMOKE pairs two of the most outspoken and controversial players of their time. Known as fiery, intense competitors during their on-court careers, Matt Barnes and Stephen Jackson are now two of the most widely respected voices by today’s crop of NBA stars. Serving as mentors to numerous players throughout the league and with their hands firmly on the pulse of the game, they have first-hand insight into the minds, lives and pressing issues facing today’s players. Barnes and Jackson, who have played alongside two generations of All-Stars, will dish on the latest news and drama from on and off the court without boundaries.